Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026 Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat loss similar to GLP-1 at three months with muscle preservation and the potential for once or twice-yearly dosing; higher dose and longer ...

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. A live webcast of the presentation can be accessed by vis ...

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].

Core Thesis - Wave Life Sciences Ltd. is positioned for significant growth with its RNA-based therapies, particularly WVE-006 and WVE-007, which could reshape its valuation and market profile [2][5][8] Pipeline and Clinical Developments - The near-term focus is on WVE-006, an RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), which has shown promising results in Phase 1b/2a trials, indicating it may become a best-in-class therapy [3][4] - WVE-007, targeting obesity through siRNA therapy, shows potential for transformative treatment, with preclinical data indicating selective fat loss while preserving lean muscle [5][6] Financial Implications - WVE-006 is partnered with GSK, allowing Wave to earn up to $525 million in milestones and high-teens royalties, which will alleviate financing pressure and support further R&D investments [4] - Successful validation of WVE-007 could lead to a stock appreciation of 40% or more, highlighting the company's potential as a rare RNA-based biotech with multiple high-value opportunities [7][8] Market Position and Growth Potential - Additional pipeline candidates, including therapies for Duchenne muscular dystrophy and Huntington's disease, enhance the company's growth prospects, with early-stage data supporting their potential [6] - The combined assets of Wave Life Sciences present a compelling risk/reward profile, with near-term catalysts expected to drive stock appreciation by 10-20% [7]

Core Insights - Wave Life Sciences Ltd. is set to announce interim data from the Phase 1 INLIGHT clinical trial for WVE-007, an investigational treatment for obesity, on December 8, 2025 [1] - The company utilizes its proprietary SpiNA design in the development of WVE-007, which targets INHBE mRNA linked to obesity [3] Group 1: WVE-007 Overview - WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, which has shown potential in improving body composition and reducing the risk of type 2 diabetes and cardiovascular disease [3] - Preclinical studies indicate that WVE-007 can lead to adipocyte shrinkage, reduced inflammation, and improved insulin sensitivity [3] - When used in conjunction with semaglutide, WVE-007 demonstrated a doubling of weight loss in mice and prevented weight regain after stopping semaglutide [3] Group 2: INLIGHT Clinical Trial - The INLIGHT trial is a first-in-human study evaluating WVE-007 in adults with overweight or obesity, focusing on safety, tolerability, and various health metrics [4] - The trial employs a 3:1 active to placebo ratio and is being conducted at multiple sites, including locations in the US [4] Group 3: Company Background - Wave Life Sciences is a biotechnology firm dedicated to RNA medicines, with a diverse pipeline addressing conditions such as obesity, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy [5] - The company's PRISM® platform integrates various RNA-targeting modalities, enabling innovative treatments for both rare and common diseases [5] - Wave Life Sciences is headquartered in Cambridge, MA, and aims to transform human health through scientific breakthroughs [5]

Summary of Wave Life Sciences Conference Call Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Focus**: Building a fully integrated RNA medicines company capable of unlocking the potential of genetic medicines, particularly in RNA editing and siRNA technologies [3][4][39] Key Programs and Developments 1. Inhibin E (WVE-007) - **Target**: Obesity, focusing on fat loss without impacting lean mass - **Mechanism**: Utilizes siRNA to knock down inhibin E, leading to significant fat loss while preserving muscle mass - **Preclinical Results**: Demonstrated a 70% reduction in activin E levels in DIO mice, translating to fat loss equivalent to GLP-1s without affecting lean mass [10][12][13] - **Clinical Data**: - 75 mg cohort showed a 55% reduction in activin E sustained over six months - 240 mg cohort achieved a 75% reduction at day 29, with ongoing decline [13][14] - **Future Outlook**: Q4 will provide three-month data on the 240 mg cohort, with further insights expected in Q1 2026 [14][20] 2. Alpha-1 Antitrypsin Deficiency (AATD) - **Mechanism**: RNA editing to convert Z protein to M protein, enhancing protein levels in patients - **Clinical Results**: At the lowest dose, patients showed a return to near-normal levels of total protein, with significant increases in M protein [32][34] - **Upcoming Data**: Focus on the 400 mg dose cohort to assess durability and editing efficiency [32][37] 3. PNPLA3 Program (WVE-008) - **Target**: Liver disease associated with homozygous mutations - **Potential Impact**: Could address a large patient population (approximately 9 million) at risk of liver diseases, with a unique mechanism that siRNAs cannot treat [39][40] Industry Context and Market Opportunity - **Obesity Treatment Landscape**: The company aims to shift the paradigm in obesity treatment from frequent dosing (weekly/monthly) to potentially once or twice a year with their siRNA therapies, addressing a significant global health issue [27][28] - **Market Size**: The global obesity market presents a substantial opportunity, with the potential to treat a billion patients worldwide [27] Important Considerations - **Kinetics of Fat Loss**: The company emphasizes the importance of understanding the kinetics of fat loss versus total weight loss, particularly in the context of preserving muscle mass [18][19][21] - **Regulatory Perspective**: The FDA's framing of healthy weight loss has influenced the company's approach to defining success in their clinical trials [17][18] Conclusion - Wave Life Sciences is positioned to make significant advancements in genetic medicine, particularly in obesity and liver disease, with promising data expected in the near future. The focus on innovative RNA technologies and the potential for long-term treatment regimens could disrupt current treatment paradigms in these areas [39][40]

Core Insights - Wave Life Sciences announced significant clinical progress with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency (AATD), highlighting the effectiveness of their proprietary RNA chemistry [2][3] - WVE-007 demonstrated up to 85% reduction in Activin E levels, indicating potential for fat loss while preserving muscle mass, with sustained effects observed for up to six months [1][7] - The company reported cash and cash equivalents of $196.2 million as of September 30, 2025, with additional funding expected to extend their cash runway into Q2 2027 [11][12] Obesity Treatment - WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, showing promise as a treatment for obesity by improving cardiometabolic health without the side effects associated with GLP-1 therapies [3][4] - Preclinical data presented at ObesityWeek® supports WVE-007's potential as a monotherapy and in combination with existing treatments, demonstrating improvements in metabolic health markers [3][4] Alpha-1 Antitrypsin Deficiency (AATD) - WVE-006 achieved key treatment goals in the RestorAATion-2 trial, restoring AAT protein levels necessary to prevent lung damage during acute exacerbations [1][5] - Clinical data showed that WVE-006 reduced mutant Z-AAT by 60% and increased wild-type M-AAT protein to 64% of serum AAT levels [1][7] Pipeline and Future Developments - Wave Life Sciences is advancing multiple candidates, including WVE-008 for liver disease and WVE-N531 for Duchenne muscular dystrophy, with expected clinical data updates in the coming quarters [3][8][12] - The company is exploring a bifunctional single oligonucleotide construct that can silence one target while editing another, showcasing their innovative approach to RNA therapeutics [8] Financial Performance - The company reported a net loss of $53.9 million for Q3 2025, an improvement from a loss of $61.8 million in the prior year [16][22] - Research and development expenses increased to $45.9 million in Q3 2025, reflecting ongoing investment in clinical trials and product development [16][22]

Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [1][3] - The company will participate in two investor conferences in November 2025, showcasing its leadership and ongoing projects [2] Conference Participation - At the Guggenheim Annual Healthcare Innovation Conference on November 11, 2025, Paul Bolno, MD, MBA, President and CEO, will engage in an analyst-led fireside chat at 10:00 a.m. ET [2] - At the Jefferies London Healthcare Conference on November 20, 2025, Dr. Bolno will participate in an analyst-led fireside chat at 8:30 a.m. GMT / 3:30 a.m. ET and in the "Anti-Obesity Panel" at 9:00 a.m. GMT / 4:00 a.m. ET [2] Company Overview - Wave Life Sciences utilizes its RNA medicines platform, PRISM, which integrates various modalities and innovations in chemistry to address both rare and common disorders [3] - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - Wave Life Sciences is headquartered in Cambridge, MA, and is committed to advancing human health by overcoming disease burdens [3]

Core Insights - Wave Life Sciences Ltd. presented preclinical data for WVE-007, a GalNAc-siRNA therapeutic aimed at treating obesity by promoting fat loss while preserving muscle mass with infrequent dosing [1][3][12] - The investigational therapy demonstrated significant reductions in Activin E levels, leading to weight loss and improved metabolic health in preclinical models and ongoing clinical trials [1][7][14] Group 1: Preclinical Data and Mechanism - WVE-007 targets INHBE mRNA, which is linked to lower levels of unhealthy visceral fat and reduced risk of type 2 diabetes and cardiovascular disease [2][3] - In preclinical studies, WVE-007 resulted in adipocyte shrinkage, decreased pro-inflammatory macrophages, reduced fibrosis, and enhanced insulin sensitivity in visceral adipose tissue [1][14] - The treatment showed a significant weight loss effect in mice, with no loss of skeletal muscle mass, indicating a healthy weight loss profile [5][14] Group 2: Clinical Trial Progress - The ongoing INLIGHT clinical trial is evaluating WVE-007 in adults with overweight or obesity, focusing on safety, tolerability, and metabolic health [11] - Recent data from the trial showed dose-dependent reductions in Activin E levels, with reductions of up to 85% observed one month after a single dose [7][11] - The treatment was reported to be safe and well-tolerated, leading to the expansion of dosing cohorts in the trial [8][11] Group 3: Future Expectations - Wave Life Sciences anticipates multiple clinical data updates from the INLIGHT trial, including body composition and weight data, starting in Q4 2025 [9] - The company aims to demonstrate the potential for WVE-007 to provide effective obesity treatment with infrequent dosing, potentially only once or twice a year [3][9]

Core Insights - Wave Life Sciences Ltd. is set to host a live webcast and conference call on November 10, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide business updates [1] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3] - The company's RNA medicines platform, PRISM®, integrates various modalities and chemistry innovations to address both rare and common disorders [3] - Wave's pipeline includes clinical programs targeting alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - The company is headquartered in Cambridge, MA, and emphasizes its mission to "Reimagine Possible" in the realm of human health [3]